Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Issues

Volume 16, Issue 24
15 December 2010
Issue Cover
All Issues
  • Cover Image

    Cover Image

    issue cover
    Intracerebral xenograft initiated from the CD133+ glioblastoma stem-like cell line GBMJ1. At the initial signs of morbidity (94 days after implantation) a representative mouse was euthanized and the brain tumor prepared for histological analyses. This figure shows the immunofluorescent analyses of GFAP (red) and III tubulin (green) with nuclei counterstained with DAPI (blue) at 20x magnification. For details, see the article by Jamal and colleagues on page 6049 of this issue.
  • PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265

Highlights

Highlights of This Issue
View articletitled, Highlights of This Issue
Open the PDF for in another window

CCR Translations

Braking Bad: Blockade of Inhibitory Pathways Improves Interleukin-15 Therapy
William E. Carson, III
View articletitled, Braking Bad: Blockade of Inhibitory Pathways Improves Interleukin-15 Therapy
Supplementary data
Open the PDF for in another window
Toward a Better Understanding of Race and Cancer
Otis W. Brawley
View articletitled, Toward a Better Understanding of Race and Cancer
Supplementary data
Open the PDF for in another window

CCR Drug Updates

Pazopanib in Renal Cell Carcinoma
James E. Ward; Walter M. Stadler
View articletitled, Pazopanib in Renal Cell Carcinoma
Open the PDF for in another window

Molecular Pathways

Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis
Xin Lu; Yibin Kang
View articletitled, Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis
Open the PDF for in another window
Targeting RET Receptor Tyrosine Kinase Activation in Cancer
John E. Phay; Manisha H. Shah
View articletitled, Targeting RET Receptor Tyrosine Kinase Activation in Cancer
Open the PDF for in another window

Review

Resveratrol: Challenges in Translation to the Clinic — A Critical Discussion
Lalita Subramanian; Sherry Youssef; Saswati Bhattacharya; Jason Kenealey; Arthur S. Polans; Paul R. van Ginkel
View articletitled, Resveratrol: Challenges in Translation to the Clinic — A Critical Discussion
Open the PDF for in another window

CCR Focus

Striving to Improve Outcomes in Oncology: Unmet Expectations in a Complex Disease
Susan E. Bates
View articletitled, Striving to Improve Outcomes in Oncology: Unmet Expectations in a Complex Disease
Open the PDF for in another window
Translating Clinical Trials into Meaningful Outcomes
Patricia M. LoRusso; Lowell E. Schnipper; David J. Stewart; Scott A. Boerner; Steven D. Averbuch; Walter Wolf
View articletitled, Translating Clinical Trials into Meaningful Outcomes
Open the PDF for in another window
Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed in the Right Direction?
Patricia M. LoRusso; Aparna B. Anderson; Scott A. Boerner; Steven D. Averbuch
View articletitled, Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed in the Right Direction?
Open the PDF for in another window
Evaluating Patient-Centered Outcomes in the Randomized Controlled Trial and Beyond: Informing the Future with Lessons from the Past
Christopher M. Booth
View articletitled, Evaluating Patient-Centered Outcomes in the Randomized Controlled Trial and Beyond: Informing the Future with Lessons from the Past
Open the PDF for in another window
Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?
Tito Fojo; David R. Parkinson
View articletitled, Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?
Open the PDF for in another window
Explaining Marginal Benefits to Patients, When “Marginal” Means Additional but Not Necessarily Small
Thomas J. Smith; Bruce E. Hillner
View articletitled, Explaining Marginal Benefits to Patients, When “Marginal” Means Additional but Not Necessarily Small
Open the PDF for in another window
The 2010 Health Care Reform Act: A Potential Opportunity to Advance Cancer Research by Taking Cancer Personally
William S. Dalton; Daniel M. Sullivan; Timothy J. Yeatman; David A. Fenstermacher
View articletitled, The 2010 Health Care Reform Act: A Potential Opportunity to Advance Cancer Research by Taking Cancer Personally
Open the PDF for in another window
The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center
Justin F. Klamerus; Suanna S. Bruinooge; Xiaobu Ye; Mandi L. Klamerus; Dorothy Damron; Dina Lansey; John C. Lowery; Luis A. Diaz, Jr.; Jean G. Ford; Norma Kanarek; Charles M. Rudin
View articletitled, The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center
Open the PDF for in another window
Value and Cancer Care: Toward an Equitable Future
Lowell E. Schnipper; Neal J. Meropol; Dan W. Brock
View articletitled, Value and Cancer Care: Toward an Equitable Future
Open the PDF for in another window

Human Cancer Biology

IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer
Zhi Liu; Dingxie Liu; Ermal Bojdani; Adel K. El-Naggar; Vasily Vasko; Mingzhao Xing
View articletitled, IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer
Supplementary data
Open the PDF for in another window

Cancer Therapy: Preclinical

Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model
Ping Yu; Jason C. Steel; Meili Zhang; John C. Morris; Thomas A. Waldmann
View articletitled, Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model
Supplementary data
Open the PDF for in another window
Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma
Saadia A. Aziz; Lucia B. Jilaveanu; Christopher Zito; Robert L. Camp; David L. Rimm; Patricia Conrad; Harriet M. Kluger
View articletitled, Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma
Supplementary data
Open the PDF for in another window
The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations
Begoña Comin-Anduix; Thinle Chodon; Hooman Sazegar; Douglas Matsunaga; Stephen Mock; Jason Jalil; Helena Escuin-Ordinas; Bartosz Chmielowski; Richard C Koya; Antoni Ribas
View articletitled, The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations
Supplementary data
Open the PDF for in another window
Microenvironmental Regulation of Glioblastoma Radioresponse
Muhammad Jamal; Barbara H. Rath; Eli S. Williams; Kevin Camphausen; Philip J. Tofilon
View articletitled, Microenvironmental Regulation of Glioblastoma Radioresponse
Supplementary data
Open the PDF for in another window
The Notch Target Hes1 Directly Modulates Gli1 Expression and Hedgehog Signaling: A Potential Mechanism of Therapeutic Resistance
Karisa C. Schreck; Pete Taylor; Luigi Marchionni; Vidya Gopalakrishnan; Eli E. Bar; Nicholas Gaiano; Charles G. Eberhart
View articletitled, The Notch Target Hes1 Directly Modulates Gli1 Expression and Hedgehog Signaling: A Potential Mechanism of Therapeutic Resistance
Supplementary data
Open the PDF for in another window
A Hypoxia- and α-Fetoprotein–Dependent Oncolytic Adenovirus Exhibits Specific Killing of Hepatocellular Carcinomas
Oh-Joon Kwon; Pyung-Hwan Kim; Steven Huyn; Lily Wu; Minjung Kim; Chae-Ok Yun
View articletitled, A Hypoxia- and α-Fetoprotein–Dependent Oncolytic Adenovirus Exhibits Specific Killing of Hepatocellular Carcinomas
Supplementary data
Open the PDF for in another window

Imaging, Diagnosis, Prognosis

Genotypic Profiling of 452 Choroidal Melanomas with Multiplex Ligation-Dependent Probe Amplification
Bertil Damato; Justyna A. Dopierala; Sarah E. Coupland
View articletitled, Genotypic Profiling of 452 Choroidal Melanomas with Multiplex Ligation-Dependent Probe Amplification
Open the PDF for in another window
Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer
Gustavo S.P. Meirelles; Heiko Schöder; Gregory C. Ravizzini; Mithat Gönen; Josef J. Fox; John Humm; Michael J. Morris; Howard I. Scher; Steven M. Larson
View articletitled, Prognostic Value of Baseline [<sup>18</sup>F] Fluorodeoxyglucose Positron Emission Tomography and <sup>99m</sup>Tc-MDP Bone Scan in Progressing Metastatic Prostate Cancer
Open the PDF for in another window
Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study
Katie M. O'Brien; Stephen R. Cole; Chiu-Kit Tse; Charles M. Perou; Lisa A. Carey; William D. Foulkes; Lynn G. Dressler; Joseph Geradts; Robert C. Millikan
View articletitled, Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study
Supplementary data
Open the PDF for in another window
A Combination of Serum Markers for the Early Detection of Colorectal Cancer
Norbert Wild; Herbert Andres; Wolfgang Rollinger; Friedemann Krause; Peter Dilba; Michael Tacke; Johann Karl
View articletitled, A Combination of Serum Markers for the Early Detection of Colorectal Cancer
Supplementary data
Open the PDF for in another window

Cancer Therapy: Clinical

CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
Mark E. Dudley; Colin A. Gross; Michelle M. Langhan; Marcos R. Garcia; Richard M. Sherry; James C. Yang; Giao Q. Phan; Udai S. Kammula; Marybeth S. Hughes; Deborah E. Citrin; Nicholas P. Restifo; John R. Wunderlich; Peter A. Prieto; Jenny J. Hong; Russell C. Langan; Daniel A. Zlott; Kathleen E. Morton; Donald E. White; Carolyn M. Laurencot; Steven A. Rosenberg
View articletitled, CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
Supplementary data
Open the PDF for in another window
Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
Raffit Hassan; Steven J. Cohen; Martin Phillips; Ira Pastan; Elad Sharon; Ronan J. Kelly; Charles Schweizer; Susan Weil; Daniel Laheru
View articletitled, Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
Open the PDF for in another window
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
Steven K. Libutti; Giulio F. Paciotti; Adriana A. Byrnes; H. Richard Alexander, Jr.; William E. Gannon; Melissa Walker; Geoffrey D. Seidel; Nargiza Yuldasheva; Lawrence Tamarkin
View articletitled, Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
Open the PDF for in another window
Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study
Denis C. Talbot; Malcolm Ranson; Joanna Davies; Michael Lahn; Sophie Callies; Valérie André; Sunil Kadam; Michael Burgess; Christopher Slapak; Anna L Olsen; Peter J. McHugh; Johann S. de Bono; Julian Matthews; Azeem Saleem; Patricia Price
View articletitled, Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study
Supplementary data
Open the PDF for in another window

Predictive Biomarkers and Personalized Medicine

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Monika Graeser; Afshan McCarthy; Christopher J. Lord; Kay Savage; Margaret Hills; Janine Salter; Nicholas Orr; Marina Parton; Ian E. Smith; Jorge S. Reis-Filho; Mitch Dowsett; Alan Ashworth; Nicholas C. Turner
View articletitled, A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Supplementary data
Open the PDF for in another window
Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer
Song Yao; William E. Barlow; Kathy S. Albain; Ji-Yeob Choi; Hua Zhao; Robert B. Livingston; Warren Davis; James M. Rae; I-Tien Yeh; Laura F. Hutchins; Peter M. Ravdin; Silvana Martino; Alan P. Lyss; C. Kent Osborne; Martin Abeloff; Gabriel N. Hortobagyi; Daniel F. Hayes; Christine B. Ambrosone
View articletitled, Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer
Open the PDF for in another window

Letters to the Editor

Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Letter
Cathy B. Moelans; Roel A. de Weger; Paul J. van Diest
View articletitled, Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Letter
Open the PDF for in another window
Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Response
Leona Downey; Robert Livingston
View articletitled, Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Response
Open the PDF for in another window
Do Rectal Cancer Patients with PIK3CA Mutations Benefit from Preoperative Radiotherapy with Regard to Local Recurrences?
Youji He; Laura J. Van't Veer; Marta Lopez-Yurda; Cornelis J.H. van de Velde; Corrie A.M. Marijnen
View articletitled, Do Rectal Cancer Patients with <em>PIK3CA</em> Mutations Benefit from Preoperative Radiotherapy with Regard to Local Recurrences?
Open the PDF for in another window
Clinical Usefulness of Microarrays for Cancer Prognosis in 2010—Letter
Serge Koscielny; Stefan Michiels
View articletitled, Clinical Usefulness of Microarrays for Cancer Prognosis in 2010—Letter
Open the PDF for in another window
Statistical Evaluation of Clinical Usefulness of Microarrays for Cancer Prognosis Needs to be Placed in the Context of Clinical Reality—Response
Weida Tong; Xiaohui Fan
View articletitled, Statistical Evaluation of Clinical Usefulness of Microarrays for Cancer Prognosis Needs to be Placed in the Context of Clinical Reality—Response
Open the PDF for in another window

Reviewers

Acknowledgment to Reviewers
View articletitled, Acknowledgment to Reviewers
Open the PDF for in another window

Advertisement

Breaking
AbbVie Inks Deal for T-Cell Engager
GSK Buys Gastrointestinal-Focused Biopharma
Eli Lilly Snaps Up PI3Kα Inhibitor
View more recent articles
Latest News
South Asian Scholars Urge Action on Cancer Inequities
Greater Certainty of Survival Valued Over Speedier Drug Access
Keto Diet Key to Fueling CARs?
View more recent articles
Research Watch
The Zinc-Binding Cysteine Proteome Comprises Targetable Cancer Vulnerabilities
Engineered Focal Oncogene Amplifications Drive Transformation and Progression
Glycolysis Dictates Response to Fasting-Mimicking Diet in Breast Cancer
View more recent articles

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.

  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2025 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept